ImmunoCellular Therapeutics, Ltd.Additional Agreement Related to Offering • May 1st, 2007 • ImmunoCellular Therapeutics, Ltd. • Biological products, (no disgnostic substances)
ImmunoCellular Therapeutics, Ltd. (the “Corporation”), is offering units (the “Units”) at a price of US$1.50 per Unit (the “Offering”) consisting of shares of the Corporation’s Common Stock (“Common Shares”) and Common Share purchase warrants (“Warrants”). RAB Special Situations (Master) Fund Limited (“RAB”) has subscribed to purchase 800,000 Units for a purchase price of $1,200,000 pursuant to a subscription agreement among the Corporation and RAB (the “Subscription Agreement”) dated as of the date hereof (the “Subscription Date”). The Common Shares and Warrants underlying the Units and the Common Shares issuable upon exercise of the Warrants are collectively referred to as the “Securities”.
